However, in MCL cells we observed a different pattern of changes since, at variance with MM cells and according to previous studies [40], bortezomib caused a rise of Mcl1 levels that was partly antagonized by the combination with CK2 inhibitors. This evidence concerns the gene MCL1 and mantle cell lymphoma.